Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 6/20 | 0.45 |
| ▸ | RAB9A | P51151 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | CCR6 | P51684 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963482 | 0.81 | SMN1; SMN2 (0.52) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL11336444 | 0.81 | ALDH1A1 (0.50) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL8100695 | 0.77 | KMT2A (0.44) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL30422583 | 0.77 | GAA (1.00) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL33272 | 0.77 | GAA (1.00) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| Bromide SCHEMBL10995945 | 0.76 | GAA (0.95) | GAAALDH1A1SMN1; SMN2TP53CYP3A4 | |
| SCHEMBL21340393 | 0.75 | KMT2A (0.43) | GAASMN1; SMN2CYP3A4KMT2ANPC1 | |
| SCHEMBL780451 | 0.75 | RAB9A (0.61) | GAAALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL30189802 | 0.75 | SMN1; SMN2 (0.51) | GAAALDH1A1SMN1; SMN2TP53KMT2A | |
| SCHEMBL799569 | 0.75 | SMN1; SMN2 (0.51) | GAAALDH1A1SMN1; SMN2TP53KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011131975-A1 | MICROSOMAL PROSTAGLANDIN E SYNTASE-1 INHIBITORS | Convergence Pharmaceuticals Limited (GB) | 2011-10-27 | — | — | WO | disclosed |
| US-8013166-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER HEALTHCARE LLC (US) | 2011-09-06 | — | — | US | disclosed |
| EP-1633722-B1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2011-08-03 | — | — | EP | disclosed |
| US-7968576-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER A | 2011-06-28 | — | — | US | disclosed |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | SMITH ROGER | 2009-10-29 | — | — | US | disclosed |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | SMITH ROGER | 2009-10-08 | — | — | US | disclosed |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER HEALTHCARE LLC (US) | 2009-08-06 | — | — | US | disclosed |
| US-7423156-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| US-7091228-B2 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| WO-2005003127-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES AS MODULATORS OF CXCR3 FUNCTION | CELLTECH R & D LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004100881-A2 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | BAYER PHARMACEUTICALS CORPORATION | 2004-11-11 | — | — | US | disclosed |
| EP-1087962-A4 | PREPARATION OF HETEROARYL COMPOUNDS | LILLY CO ELI (US) | 2001-10-04 | — | — | EP | disclosed |
| EP-1087962-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065896-A1 | PREPARATION OF HETEROARYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| US-4952589-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-08-28 | — | — | US | disclosed |
| EP-0181163-B1 | HETEROCYCLIC PHENOXY DERIVATIVES HAVING AN ANTIHISTAMINE H2 ACTIVITY | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-12-20 | — | — | EP | disclosed |
| US-4681883-A | Histamine H2 -antagonist oxazole and thiazole derivatives and compositions therefor | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-07-21 | — | — | US | disclosed |
| EP-0181163-A2 | Heterocyclic phenoxy derivatives having an antihistamine H2 activity | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224997-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | GAA 307/4885ALDH1A1 199/4885SMN1; SMN2 3975/4885 |
| US-20060194859-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | GAA 307/4885ALDH1A1 199/4885SMN1; SMN2 3975/4885 |
| US-20090270468-A1 | Preparation and use of aryl alkyl acid derivatives for the treatment of obesity | FABP4, GPR119, LIPC | GAA 307/4885ALDH1A1 199/4885SMN1; SMN2 3975/4885 |
| US-20090197795-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | GAA 307/4885ALDH1A1 199/4885SMN1; SMN2 3975/4885 |
| US-20090253762-A1 | PREPARATION AND USE OF ARYL ALKYL ACID DERIVATIVES FOR THE TREATMENT OF OBESITY | FABP4, GPR119, LIPC | GAA 307/4885ALDH1A1 199/4885SMN1; SMN2 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.